I have the plan documents and the written criteria, which took two calls to obtain.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
Concretely, what should I do, and how would I know afterwards whether I did it right?
The honest answer is that the process rewards preparation and punishes improvisation.
Obtain the medical policy for the specific drug and plan first. It lists the required diagnosis codes, thresholds, documented durations and any prerequisite therapy, and it is the checklist the reviewer works from.
| Line | Brand, insured | Compounded, subscription | Research-grade, self-tested |
|---|---|---|---|
| Product | Copay × 12 | Monthly fee × 12 | Vials × unit price |
| Consultation | Covered or copay | Bundled | Not applicable |
| Monitoring labs | Often covered | Usually not | Self-funded |
| Independent testing | Not applicable | Optional | Essential; per lot |
| Shipping | Pharmacy | Included | Per order |
| Dominant cost | Copay structure | Subscription fee | Testing |
Track the deadlines. Appeal windows are finite, and a well-founded appeal filed late is worth nothing at all.
The caveat is that this is administrative navigation and nothing here is clinical or legal advice.
Attach everything on the first submission. Incomplete is the commonest denial.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsOn the detail: this is a paperwork problem with a paperwork solution, and framing it that way is the most useful thing anyone can do.
The denial letter states a specific reason. The appeal should address that reason first and explicitly, with the missing evidence attached, rather than restating the original case.
Each criterion must be evidenced in the clinical record, dated, before the request. A criterion asserted in a covering letter but absent from the notes is the commonest reason for a denial.
Peer-to-peer review is a standard step in utilisation-management processes and resolves a meaningful share of disputes.
A prescriber has to submit the request; this is a description of what makes one succeed, not a substitute for one.
Evidence every criterion in the dated record, not in a covering letter.
The relevant point is that most denials cite a missing element rather than a clinical disagreement, and missing elements are fixable.
Where prerequisite therapy is required, the record needs the agent, the dates, the dose and the reason it was stopped. "Tried and failed" without those four elements is not documentation.
To be exact about it, approvals expire. Note the renewal date when the approval arrives, because a lapse mid-treatment is administratively identical to a fresh denial.
Research-use compounds are outside this framework entirely and are not approved for human use.
Get the criteria first. A request written blind is a request written badly.
edited 10 Apr 2026 by Dr_Nadia_Farsi — reworded for clarity after a comment
More usefully, the denial letter states the reason. That reason is the specification for the appeal.
Submit the supporting documents with the request rather than waiting to be asked. Requests denied for insufficient information are denials that a complete submission would have avoided.
Processes differ by jurisdiction and by plan, so any general description will be wrong somewhere.
Diarise the renewal date the moment approval arrives.
Answer first: a prior authorisation is a documentation exercise against published criteria, and it is won or lost on whether the record contains the required elements.
A peer-to-peer review — the prescriber speaking to the plan's reviewer — is available in many systems and resolves a meaningful proportion of denials that a written appeal would not.
A substantial proportion of denials cite incomplete documentation rather than clinical non-eligibility, which is why complete first submissions matter.
The denial reason is the appeal specification. Address it directly.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.